PAP
RNAC icon

Persistent Asset Partners’s Cartesian Therapeutics RNAC Stock Holding History

Persistent Asset Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
+22,191
New +$164K 0.07% 196

Other funds holding RNAC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Persistent Asset Partners's RNAC Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 22,191 shares worth $231K. The stake represents 0.07% of the portfolio and ranks #196 among its holdings.

31 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Persistent Asset Partners held 22,191 shares of Cartesian Therapeutics worth $231K as of Q2 2026.
  • Cartesian Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • Cartesian Therapeutics made up 0.07% of Persistent Asset Partners's portfolio in Q2 2026, its #196 holding.
  • 31 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.